Summary
71 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 26 EUR is left as net profit.
- Earnings per share grew by 17% a year over the last 3 years.
- It earns 15 EUR a year on every 100 EUR of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
- Analysts expect revenue to fall by 3.8% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.0 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue fell by 3.9% a year over 5 years. Over the last 3 years it grew by 4.1% a year. For the next fiscal year analysts expect revenue to fall by 3.8%. Earnings per share grew by 17% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 8.5 EUR
- Research and development 43 EUR
- Sales and administration 33 EUR
- Taxes and other -10 EUR
- Net profit 26 EUR
Net profit, industry median (Biotechnology) -7.3 EUR
Out of every 100 EUR of revenue, 26 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.21%
- Paid out of profit
- 31%
- Raised in a row
- 3 years
You receive $1.14 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.